Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.49 |
| ▸ | ME2 | P23368 | 1/20 | 0.47 |
| ▸ | ME1 | P48163 | 1/20 | 0.47 |
| ▸ | ME3 | Q16798 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669690 | 0.87 | HDAC3 (0.46) | KDM4ESMN1; SMN2PANK3ME2ME1 | |
| SCHEMBL3671024 | 0.86 | SCD (0.47) | KDM4ESMN1; SMN2PANK3SCDL3MBTL1 | |
| SCHEMBL3671089 | 0.86 | SCD (0.59) | KDM4ESMN1; SMN2PANK3ME2ME1 | |
| SCHEMBL3677650 | 0.85 | SCD (0.46) | KDM4ESMN1; SMN2PANK3ME2ME1 | |
| SCHEMBL3677770 | 0.85 | SMN1; SMN2 (0.55) | KDM4ESMN1; SMN2PANK3ME2ME1 | |
| SCHEMBL3668916 | 0.84 | SMN1; SMN2 (0.54) | KDM4ESMN1; SMN2PANK3ME2ME1 | |
| SCHEMBL3667701 | 0.83 | ME2 (0.46) | SMN1; SMN2ME2ME1ME3ENPP2 | |
| SCHEMBL3677191 | 0.83 | SMN1; SMN2 (0.53) | KDM4ESMN1; SMN2PANK3ME2ME1 | |
| SCHEMBL3675164 | 0.83 | KDM4E (0.53) | KDM4ESMN1; SMN2PANK3ME2ME1 | |
| SCHEMBL3673900 | 0.83 | SMN1; SMN2 (0.51) | KDM4ESMN1; SMN2PANK3ME2ME1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | claimed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | claimed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | claimed |
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | disclosed |
| EP-2266566-A2 | Nicotinamide derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | NAMPT, NNT, NNMT | KDM4E 3385/4885SMN1; SMN2 112/4885PANK3 1531/4885 |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | APP, BACE1, PSEN1 | KDM4E 4395/4885SMN1; SMN2 123/4885PANK3 4000/4885 |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NAMPT, NNT, NNMT | KDM4E 3385/4885SMN1; SMN2 112/4885PANK3 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.